HOME >> MEDICINE >> NEWS
New long-term data analyses for Bifeprunox show favorable effects vs. placebo

Marietta, Ga., May 22, 2007 Solvay Pharmaceuticals, Inc., Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), and Lundbeck A/S presented clinical study results on bifeprunox, an investigational treatment for adult patients diagnosed with schizophrenia, today at the 2007 annual meeting of the American Psychiatric Association. New analyses of six-month data in stabilized adult patients with schizophrenia from a double-blind, placebo-controlled study demonstrated that bifeprunox maintained stability vs. placebo and displayed a favorable weight and lipid profile comparable with placebo.

"Schizophrenia is a chronic, lifelong illness, and long-term management of the illness presents many challenges," comments Daniel Casey, M.D., Professor, Psychiatry and Neurology, Oregon Health and Science University. "Clinicians need new treatment options to help patients manage schizophrenia over the long term."

A synopsis of abstracts containing bifeprunox data presented at the meeting follows:

In analyses of data from one Phase 3, six-month, randomized, double-blind, placebo-controlled study:

  • Compared with placebo, bifeprunox significantly prolonged time to deterioration over six months.

  • Bifeprunox patients experienced decreases in body weight and body mass index vs. placebo over six months.

  • Bifeprunox patients showed favorable effects on total cholesterol, triglycerides, very low-density lipoprotein and low-density lipoprotein, comparable with placebo over a six-month period.

In these analyses, the most common side effects reported with bifeprunox (incidence of greater than or equal to 5 percent and twice the placebo rate) included nausea, vomiting, dizziness, anorexia, akathisia, dyskinesia and asthenia.

"We are encouraged by these additional analyses of clinical data, which underscore bifeprunox's favorable weight and lipid profile," says Earl Sands, M.D., Vice Presi
'"/>

Contact: Neil Hirsch
neil.hirsch@solvay.com
770-578-2170
HealthStar PR
22-May-2007


Page: 1 2

Related medicine news :

1. Smoking may strongly increase long-term risk of eye disease
2. Stem cell transplantation procedure results in long-term survival for amyloidosis patients
3. Vaxfectin-formulated measles DNA vaccine elicits long-term protection in nonhuman primates
4. Ulcerative colitis remission rates from long-term safety study of LIALDA presented at DDW
5. Angioplasty reduces long-term cardiac risk among heart patients with silent ischemia
6. Disease management programs improve long-term outcomes
7. Breast cancer survivors experience long-term heart disease risk from radiotherapy
8. Study demonstrates long-term durability of Plicator procedure
9. Radiation therapy combo cures prostate cancer long-term
10. Individualized strategies needed for prevention of malaria in long-term travelers
11. IMRT versus 3D CRT for prostate cancer, new long-term data assesses side effects

Post Your Comments:
(Date:6/19/2013)... Arbor, Mich. Children had half as many ... evening office hours on five or more days a ... at C.S. Mott Children,s Hospital and Johns Hopkins University. ... in The Journal of Pediatrics and will ... "These findings are an important step in understanding where ...
(Date:6/19/2013)... (PROVIDENCE, R.I.) Casual, no-strings sexual encounters are ... students more likely than others to "hook up"? ... Hospital,s Centers for Behavioral and Preventive Medicine, published ... , suggests there are certain factors and behaviors ... women. , "Given the potential for negative ...
(Date:6/19/2013)... body,s system for repairing damage to the genetic material ... it may seem, those compounds are sparking optimism as ... a mutation in BRCA, a gene that made headlines ... The compounds, termed PARP inhibitors, are the topic of ... Chemical & Engineering News . C&EN is the weekly ...
(Date:6/19/2013)... at Louisiana State University have developed a method for ... relies on understanding the genetic interaction between single nucleotide ... prostate cancer,s aggressiveness to avoid unnecessary radical treatment. ... PLOS ONE in April. , According to ... all cancers and 9 percent of cancer deaths. It ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Alternatives, a ... some patients to quit using drugs while allowing them ... Jaffe, the founders of Alternatives, believe that abstinence-only approaches ... they enter treatment and that this approach hurts instead ... people in the United States need treatment for addiction ...
Breaking Medicine News(10 mins):Health News:Extended primary care office hours might help keep kids out of the emergency department 2Health News:Why are some college students more likely to 'hook up'? 2Health News:Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 3
(Date:6/19/2013)... Calif. , June 19, 2013   ... today announces a licensing agreement granting Suzhou Ribo ... and manufacture siRNA therapeutics in China ...  Ribo will formulate proprietary siRNA molecules in combination ... designed to address human diseases with high unmet ...
(Date:6/19/2013)... 19. Juni 2013 Specialty ... der Entwicklung von SCS microRESIST™, einer ... der Beschichtung mit Parylene gelungen ist. ... biokompatiblem Parylene mit antimikrobiellen Eigenschaften und ... Mikroorganismen auf beschichteten medizinischen Geräten. ...
(Date:6/18/2013)... 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ICPT ... development and commercialization of novel bile acid therapeutics to ... an underwritten public offering of 1,730,000 shares of its ... per share.  In addition, Intercept has granted the underwriters ... 259,500 shares of common stock. All of ...
Breaking Medicine Technology:Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
Cached News: